首页> 美国卫生研究院文献>Clinical Endoscopy >Non-Steroidal Anti-Inflammatory Drug-Induced Enteropathy
【2h】

Non-Steroidal Anti-Inflammatory Drug-Induced Enteropathy

机译:非甾体抗炎药诱发的肠病

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most commonly prescribed drugs in the world. NSAID-induced lower gastrointestinal (GI) complications are increasing while upper GI complications are decreasing. Lower GI events accounted for 40% of all serious GI events in patients on NSAIDs. Capsule endoscopy and device assisted enteroscopy are available for detection of small intestinal lesions. Capsule endoscopy studies have demonstrated that NSAIDs use in healthy volunteers raised the incidence (55% to 75%) of intestinal damage. It appears that selective cyclooxygenase-2 inhibitors (coxibs) improved upper and lower GI safety based on results of clinical trials. Selective coxibs are still capable of triggering GI adverse events and cardiovascular toxicity issues were the main focus of concerns. Unfortunately, definite strategies are not available to prevent or heal NSAID-induced intestinal injuries. Thus, there is still a strong clinical need for effective drugs with improved safety profiles than the existing NSAIDs.
机译:非甾体抗炎药(NSAIDs)是世界上最常用的处方药之一。 NSAID引起的下消化道(GI)并发症正在增加,而上消化道的并发症正在减少。较低的胃肠道事件占接受NSAID的所有严重胃肠道事件的40%。胶囊内窥镜检查和设备辅助肠镜检查可用于检测小肠病变。胶囊内窥镜检查研究表明,在健康志愿者中使用NSAID可以提高肠道损伤的发生率(55%至75%)。根据临床试验结果显示,选择性环氧合酶2抑制剂(coxibs)可以提高胃肠道安全性的上限和下限。选择性coxibs仍然能够引发胃肠道不良事件,而心血管毒性问题是人们关注的主要焦点。不幸的是,尚无确定的策略来预防或治愈NSAID引起的肠道损伤。因此,与现有的NSAID相比,仍然强烈需要具有改善的安全性的有效药物的临床需求。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号